Riferimento farmaci
Empagliflozin-linagliptin-metformin
Empagliflozin-linagliptin-metformin is a medicine in the class gastrointestinal tract. It is used for diabetes mellitus.
- Classe del farmaco: Gastrointestinal Tract
- Indicato per: diabetes mellitus
Ultimo aggiornamento
Per operatori sanitari — solo a scopo di riferimento. Questa pagina è una sintesi breve, non è un parere medico e non sostituisce il RCP ufficiale né il giudizio clinico. Verificare sempre prima di prescrivere o dispensare.
Il contenuto clinico di questa pagina è disponibile solo in inglese.
In breve
- Classe del farmaco
- Gastrointestinal Tract
- Forme farmaceutiche comuni
- compressa
- Dosaggi comuni
- 1000 mg
- Nomi commerciali
- 7
- Paesi e mercati
- 2
Per cosa si usa
Come agisce
Empagliflozin: SGLT2 inhibitor; SGLT2 is expressed in the proximal renal tubules and is responsible for the majority of the reabsorption of filtered glucose from the tubular lumen; SGLT2 inhibitors reduce glucose reabsorption and lower the renal threshold for glucose, thereby increasing urinary glucose excretion
Dose abituale nell'adulto (sintesi del foglio illustrativo)
Type 2 Diabetes Mellitus: Indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus (T2DM)
Gravidanza e allattamento
- Gravidanza
- Unsafe Based on animal data showing adverse renal effects from empagliflozin, use is not recommended during the second and third trimesters of pregnancy
- Allattamento
- Unsafe Since human kidney maturation occurs in utero and during the first 2 years of life when lactational exposure may occur, there may be risk to the developing human kidney, advise patients that use is not recommended while breastfeeding
Effetti indesiderati segnalati
- Nasopharingitis
- Constipation
- Gastroenteritis
- Urinary tract infections
- Hypoglycaemia
- Diarrhea
Avvertenze in evidenza
- Postmarketing cases of metformin-associated lactic acidosis have resulted in death, hypothermia, hypotension, and resistant bradyarrhythmias Onset of metformin-associated lactic acidosis is often subtle, accompanied only by nonspecific symptoms (eg, malaise, myalgias, respiratory distress, somnolence, abdominal pain) Metformin-associated lactic acidosis was characterized by elevated blood lactate levels (>5 mmol/L), anion gap acidosis (without evidence of ketonuria or ketonemia), an increased lactate/pyruvate ratio, and metformin plasma levels generally >5 mcg/mL Risk factors include…
Controindicazioni
- Hypersensitivity to empagliflozin, linagliptin, metformin, or any of the excipients in the product
- Metabolic acidosis, including diabetic ketoacidosis
- Severe renal impairment (eGFR <30 mL/min/1.73 m2), ESRD, or dialysis
Chi deve prestare attenzione
- Serious hypersensitivity reactions, (eg, angioedema) in patients treated with empagliflozin reported postmarketing; discontinue therapy and treat promptly if it occurs per standard of care
- There have been reports of acute pancreatitis, including fatal pancreatitis; if pancreatitis suspected, promptly discontinue
- Heart failure observed with 2 other DPP-4 inhibitors; consider risks and benefits in patients with known risk factors for heart failure; monitor for signs and symptoms
Informare il farmacista o il medico di gravidanza o allattamento, malattie renali o epatiche, allergie e di ogni altro farmaco o integratore assunto.
Per gli utenti Pro+
Sblocca la pagina completa
Crei un account e avvii una prova di Pro+ per aprire la monografia completa di Empagliflozin-linagliptin-metformin: dosi, gravidanza e allattamento, effetti indesiderati, avvertenze e tutte le interazioni.
- Dosing by age, kidney and liver function, and further dose lines
- Renal and hepatic dose adjustments
- Paediatric dosing
- How to give it
- Pharmacokinetics
- Patient counselling points
- Food interactions
Provi Pro+ gratis per 14 giorni sul web. Nessuna carta.
Altri farmaci della stessa classe
Domande frequenti
What is Empagliflozin-linagliptin-metformin used for?
Empagliflozin-linagliptin-metformin is a medicine in the class gastrointestinal tract. It is used for Diabetes mellitus.
What side effects have been reported with Empagliflozin-linagliptin-metformin?
Nasopharingitis, Constipation, Gastroenteritis, Urinary tract infections, Hypoglycaemia, Diarrhea. Serious warning: Postmarketing cases of metformin-associated lactic acidosis have resulted in death, hypothermia, hypotension, and resistant bradyarrhythmias Onset of metformin-associated lactic acidosis is often subtle, accompanied only by nonspecific symptoms (eg, malaise, myalgias, respiratory distress,…
Can Empagliflozin-linagliptin-metformin be taken in pregnancy or while breastfeeding?
Pregnancy: Unsafe. Based on animal data showing adverse renal effects from empagliflozin, use is not recommended during the second and third trimesters of pregnancy Breastfeeding: Unsafe. Since human kidney maturation occurs in utero and during the first 2 years of life when lactational exposure may occur, there may be risk to the developing human kidney, advise patients that use is not recommended while breastfeeding
What does Empagliflozin-linagliptin-metformin interact with?
MediHelp does not list a checked interaction for Empagliflozin-linagliptin-metformin yet. Always tell your pharmacist about every medicine you take.
Monografie complete, posologie e verifica delle interazioni nell'app MediHelp
Apra il riferimento completo, verifichi le interazioni tra più farmaci e usi gli strumenti di posologia nell'app MediHelp.
